Zhang, Jiancheng
Ma, Li
Wan, Xiayun
Shan, Jiajing
Qu, Youge
Hashimoto, Kenji http://orcid.org/0000-0002-8892-0439
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP20dm0107119)
Article History
Received: 26 April 2021
Accepted: 27 May 2021
First Online: 27 July 2021
Declarations
:
: All animal experiments were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, USA, and approved by the Chiba University Institutional Animal Care and Use Committee (permission number: 2–308).
: Not applicable.
: Dr. Hashimoto is the inventor of filed patent applications on “The use of <i>R</i>-ketamine in the treatment of psychiatric diseases,” “(<i>S</i>)-norketamine and salt thereof as pharmaceutical,” “<i>R</i>-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder,” “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases,” and “<i>R</i>-ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder” by the Chiba University. Dr. Hashimoto also declares that he has received research support and consultant from Dainippon Sumitomo, Otsuka, and Taisho. The other authors have no conflict of interest.